ATE366238T1 - Heterocyclischen inhibitoren von glycogen synthase kinase gsk-3 - Google Patents

Heterocyclischen inhibitoren von glycogen synthase kinase gsk-3

Info

Publication number: ATE366238T1
Authority: AT; Austria
Prior art keywords: glycogen synthase; synthase kinase; disease; heterocyclic inhibitors; gsk
Prior art date: 2000-05-11

Application number

AT01928117T

Other languages

English (en)

Inventor

Gil Ana Martinez

Morera Ana Castro

Martin Maria Concepcion Perez

Mercedes Alonso Cascon

Isabel Diaz

Munoz Francisco Jose Moreno

Jurado Wandosell

Original Assignee

Consejo Superior Investigacion

Univ Madrid Autonoma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-05-11

Filing date

2001-05-11

Publication date

2007-07-15

2000-05-11 Priority claimed from ES200001185A external-priority patent/ES2166328B1/es

2001-05-11 Application filed by Consejo Superior Investigacion, Univ Madrid Autonoma filed Critical Consejo Superior Investigacion

2007-07-15 Application granted granted Critical

2007-07-15 Publication of ATE366238T1 publication Critical patent/ATE366238T1/de

Links

102000002254 Glycogen Synthase Kinase 3 Human genes 0.000 title abstract 2
239000003112 inhibitor Substances 0.000 title 1
201000010099 disease Diseases 0.000 abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
208000024827 Alzheimer disease Diseases 0.000 abstract 1
206010003210 Arteriosclerosis Diseases 0.000 abstract 1
108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 abstract 1
102000004877 Insulin Human genes 0.000 abstract 1
108090001061 Insulin Proteins 0.000 abstract 1
206010054949 Metaplasia Diseases 0.000 abstract 1
206010028980 Neoplasm Diseases 0.000 abstract 1
201000004681 Psoriasis Diseases 0.000 abstract 1
208000011775 arteriosclerosis disease Diseases 0.000 abstract 1
201000011510 cancer Diseases 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
230000001419 dependent effect Effects 0.000 abstract 1
206010012601 diabetes mellitus Diseases 0.000 abstract 1
230000003463 hyperproliferative effect Effects 0.000 abstract 1
229940125396 insulin Drugs 0.000 abstract 1
230000015689 metaplastic ossification Effects 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
208000037803 restenosis Diseases 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
- C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
- C07D207/456—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
- C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
- C07D285/13—Oxygen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/385—Saturated compounds containing a keto group being part of a ring
- C07C49/395—Saturated compounds containing a keto group being part of a ring of a five-membered ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
- C07C49/597—Unsaturated compounds containing a keto groups being part of a ring of a five-membered ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/12—Oxygen or sulfur atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/36—Sulfur atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Diabetes (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Hematology (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Endocrinology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

AT01928117T 2000-05-11 2001-05-11 Heterocyclischen inhibitoren von glycogen synthase kinase gsk-3 ATE366238T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
ES200001185A ES2166328B1 (es)	2000-05-11	2000-05-11	Inhibidores heterociclicos del enzima gsk 3 utiles en el tratamiento de procesos neurodegenerativos e hiperproliferativos
GB0030284A GB0030284D0 (en)	2000-05-11	2000-12-12	Enzyme inhibitors

Publications (1)

Publication Number	Publication Date
ATE366238T1 true ATE366238T1 (de)	2007-07-15

Family

ID=26156184

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT01928117T ATE366238T1 (de)	2000-05-11	2001-05-11	Heterocyclischen inhibitoren von glycogen synthase kinase gsk-3

Country Status (19)

Country	Link
US (3)	US6872737B2 (de)
EP (1)	EP1286964B1 (de)
KR (1)	KR100812407B1 (de)
CN (1)	CN100358867C (de)
AT (1)	ATE366238T1 (de)
AU (1)	AU783615B2 (de)
BR (1)	BR0110734A (de)
CA (1)	CA2408747C (de)
CY (1)	CY1106826T1 (de)
CZ (1)	CZ296087B6 (de)
DE (1)	DE60129222T2 (de)
DK (1)	DK1286964T3 (de)
ES (1)	ES2288948T3 (de)
HU (1)	HUP0302002A3 (de)
IL (1)	IL152721A0 (de)
MX (1)	MXPA02011079A (de)
PL (1)	PL209780B1 (de)
RU (1)	RU2294931C2 (de)
WO (1)	WO2001085685A1 (de)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE60129222T2 (de) *	2000-05-11	2008-03-06	Consejo Superior de Investigaciónes Científicas	Heterocyclischen inhibitoren von glycogen synthase kinase gsk-3
WO2003018011A1 (en) *	2001-08-24	2003-03-06	Wyeth Holdings Corporation	5-(substituted)-5-(substitutedsulfonyl or sulfanyl)thiazolidine-2,4-diones useful for inhibition of farnesyl-protein transferase
WO2003018554A1 (en)	2001-08-24	2003-03-06	Wyeth Holdings Corporation	3-substituted-3-(substitutedsulfonyl or sulfanyl)pyrrolidine-2,5-diones useful for inhibition of farnesyl-protein transferase
US20050202559A1 (en) *	2002-10-29	2005-09-15	Scott Pownall	Cancer treatment by metabolic modulations
GB0303319D0 (en)	2003-02-13	2003-03-19	Novartis Ag	Organic compounds
GB0327908D0 (en) *	2003-12-02	2004-01-07	Neuropharma Sa	GSK-3 inhibitors isolated from marine organisms
SE0303570L (sv) *	2003-12-03	2005-06-04	Microdrug Ag	Fukt-känslig medicinsk produkt
EP1574499A1 (de) *	2004-03-08	2005-09-14	DKFZ Deutsches Krebsforschungszentrum	DNA-Methylerungshemmer in Tumorzellen
EP1586318A1 (de)	2004-04-05	2005-10-19	Neuropharma S.A.U.	Thiadiazolidinone als GSK3-Inhibitoren
WO2006034207A2 (en) *	2004-09-17	2006-03-30	Vanderbilt University	Use of gsk3 inhibitors in combination with radiation therapies
WO2006045581A1 (en) *	2004-10-21	2006-05-04	Neuropharma, S.A.	The use of 1, 2, 4-thiadiazolidine-3, 5-diones as ppar activators
EP1838685A4 (de) *	2005-01-10	2010-01-27	Astrazeneca Ab	Derivate von isothiazol-3-(2h)-thion-1,1-dioxiden als liver-x-rezeptormodulatoren
SE0500055D0 (sv) *	2005-01-10	2005-01-10	Astrazeneca Ab	Therapeutic agents 3
SE0500056D0 (sv) *	2005-01-10	2005-01-10	Astrazeneca Ab	Therapeutic agents 4
MX2007008370A (es) *	2005-01-10	2007-08-21	Astrazeneca Ab	Derivados de 1,1-dioxidos de isotiazol-3 (2h) -ona como moduladores del receptor del higado x.
SE0500058D0 (sv) *	2005-01-10	2005-01-10	Astrazeneca Ab	Therapeutic agents 5
DE602006017965D1 (de)	2005-02-09	2010-12-16	Arqule Inc	Maleimid-derivate, pharmazeutische zusammensetzungen und verfahren zur behandlung von krebs
ES2258406B1 (es) *	2005-02-10	2007-12-01	Neuropharma, S.A.	Uso de compuestos heterociclicos como agentes neurogenicos.
EP2258359A3 (de)	2005-08-26	2011-04-06	Braincells, Inc.	Neurogenese durch Modulation des Muscarinrezeptors mit Sabcomelin
JP2009506069A (ja)	2005-08-26	2009-02-12	ブレインセルス，インコーポレイティド	ムスカリン性受容体調節による神経発生
JP2009512711A (ja)	2005-10-21	2009-03-26	ブレインセルス，インコーポレイティド	Ｐｄｅ阻害による神経新生の調節
EP2314289A1 (de)	2005-10-31	2011-04-27	Braincells, Inc.	Gaba-rezeptor-vermittelte modulation von neurogenese
US20100216734A1 (en)	2006-03-08	2010-08-26	Braincells, Inc.	Modulation of neurogenesis by nootropic agents
AU2007249399A1 (en)	2006-05-09	2007-11-22	Braincells, Inc.	Neurogenesis by modulating angiotensin
CA2651862A1 (en)	2006-05-09	2007-11-22	Braincells, Inc.	5 ht receptor mediated neurogenesis
US8168667B2 (en)	2006-05-31	2012-05-01	Galapagos Nv	Imidazolidine derivatives, uses therefor, preparation thereof and compositions comprising such
US9180118B2 (en)	2006-07-18	2015-11-10	University Of Rochester	Thiadiazolidinone derivatives
WO2008030651A1 (en)	2006-09-08	2008-03-13	Braincells, Inc.	Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en)	2006-09-19	2010-07-22	Braincells, Inc.	Modulation of neurogenesis by ppar agents
WO2008057930A2 (en)	2006-11-02	2008-05-15	Aestus Therapeutics, Inc.	Methods of treating neuropathic pain with retinoic acid receptor agonists
US8304425B2 (en)	2007-06-22	2012-11-06	Arqule, Inc.	Pyrrolidinone, pyrrolidine-2,5-dione, pyrrolidine and thiosuccinimide derivatives, compositions and methods for treatment of cancer
CA2690782C (en)	2007-06-22	2016-02-02	Arqule, Inc.	Compositions and methods for treatment of cancer
KR20100024494A (ko)	2007-06-22	2010-03-05	아르퀼 인코포레이티드	퀴나졸리논 화합물 및 이의 사용 방법
UA105005C2 (uk) *	2008-06-16	2014-04-10	Юніверсіті Оф Теннессі Рісерч Фаундейшн	Сполуки для лікування раку
US9029408B2 (en)	2008-06-16	2015-05-12	Gtx, Inc.	Compounds for treatment of cancer
US9447049B2 (en)	2010-03-01	2016-09-20	University Of Tennessee Research Foundation	Compounds for treatment of cancer
GB2463514C (en)	2008-09-11	2018-09-26	Galapagos Nv	Imidazolidine compounds and uses therefor
US20100216805A1 (en)	2009-02-25	2010-08-26	Braincells, Inc.	Modulation of neurogenesis using d-cycloserine combinations
CN101519372B (zh) *	2009-04-01	2011-07-20	深圳市盛捷生物技术有限公司	用作GSK3抑制剂的苯并[e]异吲哚-1,3-二酮化合物及其制备
HUE027263T2 (en) *	2009-07-08	2016-10-28	Baltic Bio Ab	1,2,4-thiazolidin-3-one derivatives and their use in the treatment of cancer
ITNA20090047A1 (it) *	2009-07-16	2011-01-17	Adele Bolognese	Agenti antitumorali con attività inibitoria di proteine di prenilazione, processo di preparazione e impieghi in campo medico
EP2515914A4 (de) *	2009-12-23	2013-09-11	Scripps Research Inst	Tyrosinbiokonjugation durch wässrige ene-ähnliche reaktionen
EP3064204A1 (de)	2010-03-01	2016-09-07	GTx, Inc.	Verbindungen zur behandlung von krebs
WO2011151359A1 (en)	2010-06-02	2011-12-08	Noscira, S.A.	Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative
US11068954B2 (en)	2015-11-20	2021-07-20	Voicemonk Inc	System for virtual agents to help customers and businesses
BR112013015774A2 (pt)	2010-12-01	2018-05-22	Nissan Chemical Industries Ltd	compostos de pirazol tendo efeito terapêutico sobre mieloma múltiplo.
WO2012149335A2 (en) *	2011-04-28	2012-11-01	Richard Neubig	Small molecule inhibitors of rgs proteins
EP2527323A1 (de)	2011-05-24	2012-11-28	Noscira, S.A.	Harnstoffcarbonyldisulfidderivate und deren therapeutische Verwendungen
WO2013020024A2 (en) *	2011-08-03	2013-02-07	Karyopharm Therapeutics, Inc.	Maleimide compounds and methods of treatment
WO2013108026A1 (en)	2012-01-17	2013-07-25	Baltic Bio Ab	Thiadiazolone derivatives useful in the treatment of diabetes
US9371299B2 (en)	2012-02-24	2016-06-21	Asd Therapeutics Partners, Llc	Thiadiazolidinediones as GSK-3 inhibitors
CN103992312A (zh) *	2013-02-18	2014-08-20	江苏欧威医药有限公司	1,2,4-噻二唑-3,5-二酮衍生物及其药物组合物和应用
RU2522449C1 (ru) *	2013-03-14	2014-07-10	Общество с ограниченной ответственностью "Лечебное питание"	Средство, обладающее антипролиферативным и антиметастатическим действием, для лечения опухолевых заболеваний
US9949961B2 (en) *	2013-03-14	2018-04-24	Rahimdzhan Roziev	Agent for the prophylaxis and/or treatment of neoplastic diseases
WO2014159356A1 (en)	2013-03-14	2014-10-02	The Brigham And Women's Hospital, Inc.	Compositions and methods for epithelial stem cell expansion and culture
US9795584B2 (en)	2013-07-30	2017-10-24	University Of South Florida	Treating an atypical protein kinase C enzyme abnormality
US20170165230A1 (en)	2014-04-09	2017-06-15	Christopher Rudd	Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity
IL299964A (en)	2014-09-03	2023-03-01	Massachusetts Inst Technology	Preparations, systems and methods for producing hair cells in the inner ear to treat hearing loss
WO2016090355A2 (en) *	2014-12-05	2016-06-09	Massachusetts Institute Of Technology	Catechol-rich polymers from n-substituted maleimides
KR20170129769A (ko)	2015-03-17	2017-11-27	리제너론 파아마슈티컬스, 인크.	아미노산 아실화 시약 및 이의 사용 방법
JP2019506153A (ja)	2016-01-08	2019-03-07	マサチューセッツインスティテュートオブテクノロジー	分化した腸内分泌細胞およびインスリン産生細胞の作製
US10201540B2 (en)	2016-03-02	2019-02-12	Frequency Therapeutics, Inc.	Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
US10213511B2 (en)	2016-03-02	2019-02-26	Frequency Therapeutics, Inc.	Thermoreversible compositions for administration of therapeutic agents
US11260130B2 (en)	2016-03-02	2022-03-01	Frequency Therapeutics, Inc.	Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV
CN110392686A (zh)	2016-12-30	2019-10-29	频率治疗公司	1h-吡咯-2,5-二酮化合物以及使用它们来诱导干/祖支持细胞自我更新的方法
RU2761429C2 (ru) *	2018-06-13	2021-12-08	Общество с ограниченной ответственностью "Тиацен"	Средство, обладающее противоопухолевым действием, для лечения онкологических заболеваний
WO2020037326A1 (en)	2018-08-17	2020-02-20	Frequency Therapeutics, Inc.	Compositions and methods for generating hair cells by downregulating foxo
CA3109647A1 (en)	2018-08-17	2020-02-20	Frequency Therapeutics, Inc.	Compositions and methods for generating hair cells by upregulating jag-1
US20220133740A1 (en)	2019-02-08	2022-05-05	Frequency Therapeutics, Inc.	Valproic acid compounds and wnt agonists for treating ear disorders
CN110698380B (zh) *	2019-10-24	2021-01-15	华东理工大学	一种内酰胺衍生物及其制备方法与应用
AU2022219157A1 (en)	2021-02-11	2023-08-10	Venca Research, Inc.	Compositions and methods for treating arrhythmogenic cardiomyopathy
EP4340832A1 (de)	2021-05-21	2024-03-27	Amo Pharma Ltd.	Verfahren zur behandlung von durch rna-repeat vermittelten erkrankungen mit einer rna-repeat-bindenden verbindung
EP4094760A1 (de)	2021-05-24	2022-11-30	Consejo Superior De Investigaciones Científicas	Thiadiazolidinone zur verwendung in der behandlung von gliedergürtel-muskeldystrophie
CN115197167B (zh) *	2022-07-22	2023-07-28	中国药科大学	1,2,4-噻二唑烷-3,5-二酮化合物及其制备方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2863803A (en) *	1957-05-13	1958-12-09	Stauffer Chemical Co	Protecting materials against fungi by applying substituted dithiono and thiono-oxo-thiadiazolidines
US3301894A (en) *	1964-11-16	1967-01-31	Olin Mathieson	S-[nu'-(chlorocarbonyl)-amino] isothiocarbamyl chlorides and their preparation
DE1670701A1 (de)	1966-05-23	1970-11-12	Bayer Ag	Verfahren zur Darstellung von Thiaimidazolidinen
US3900485A (en) *	1967-02-10	1975-08-19	Velsicol Chemical Corp	New substituted 1,2,4-thiadiazolidine-3,5-diones
US3534057A (en) *	1968-05-28	1970-10-13	Velsicol Chemical Corp	Halogenation process for the production of certain oxadiazolidines and thiadiazolidines
DE2109755A1 (de)	1971-03-02	1972-09-07	Badische Anilin- & Soda-Fabrik Ag, 6700 Ludwigshafen	Substituierte Thiadiazolidindione
US4183816A (en) *	1978-11-01	1980-01-15	Olin Corporation	Use of 2,4-di(lower alkyl)-1,2,4-thiadiazolidin-3,5-diones as additives for functional fluids
JPS58216177A (ja)	1982-06-10	1983-12-15	Sumitomo Chem Co Ltd	フエニルチアジアゾリジンジオン誘導体、その製造法および該化合物を有効成分として含有する除草剤
ATE456367T1 (de) *	1993-12-23	2010-02-15	Lilly Co Eli	Proteinkinase c inhibitoren
JP3714685B2 (ja) *	1994-05-18	2005-11-09	第一サントリーファーマ株式会社	ハイメニアルディシン及びその誘導体並びにそれらの合成中間体の製造法並びにその合成中間体
DE4420522A1 (de) *	1994-06-13	1995-12-14	Bayer Ag	Bakterizide Thiadiazolidinone
WO2000021927A2 (en) *	1998-10-08	2000-04-20	Smithkline Beecham Plc	Pyrrole-2,5-diones as gsk-3 inhibitors
GB9828640D0 (en) *	1998-12-23	1999-02-17	Smithkline Beecham Plc	Novel method and compounds
GB9918180D0 (en) *	1999-08-02	1999-10-06	Smithkline Beecham Plc	Novel compositions
DE60129222T2 (de)	2000-05-11	2008-03-06	Consejo Superior de Investigaciónes Científicas	Heterocyclischen inhibitoren von glycogen synthase kinase gsk-3
GB0012056D0 (en)	2000-05-18	2000-07-12	Consejo Superior Investigacion	Model for neurodegenerative disease
EP1586318A1 (de)	2004-04-05	2005-10-19	Neuropharma S.A.U.	Thiadiazolidinone als GSK3-Inhibitoren

2001
- 2001-05-11 DE DE60129222T patent/DE60129222T2/de not_active Expired - Lifetime
- 2001-05-11 PL PL359671A patent/PL209780B1/pl unknown
- 2001-05-11 AT AT01928117T patent/ATE366238T1/de active
- 2001-05-11 RU RU2002133222/04A patent/RU2294931C2/ru not_active IP Right Cessation
- 2001-05-11 KR KR1020027015132A patent/KR100812407B1/ko not_active Expired - Fee Related
- 2001-05-11 CN CNB01812738XA patent/CN100358867C/zh not_active Expired - Lifetime
- 2001-05-11 ES ES01928117T patent/ES2288948T3/es not_active Expired - Lifetime
- 2001-05-11 EP EP01928117A patent/EP1286964B1/de not_active Expired - Lifetime
- 2001-05-11 BR BR0110734-8A patent/BR0110734A/pt not_active Application Discontinuation
- 2001-05-11 IL IL15272101A patent/IL152721A0/xx unknown
- 2001-05-11 DK DK01928117T patent/DK1286964T3/da active
- 2001-05-11 HU HU0302002A patent/HUP0302002A3/hu unknown
- 2001-05-11 MX MXPA02011079A patent/MXPA02011079A/es active IP Right Grant
- 2001-05-11 WO PCT/GB2001/002100 patent/WO2001085685A1/en not_active Ceased
- 2001-05-11 CZ CZ20023692A patent/CZ296087B6/cs not_active IP Right Cessation
- 2001-05-11 CA CA2408747A patent/CA2408747C/en not_active Expired - Lifetime
- 2001-05-11 AU AU54981/01A patent/AU783615B2/en not_active Ceased
2002
- 2002-11-08 US US10/290,569 patent/US6872737B2/en not_active Expired - Lifetime
2004
- 2004-08-12 US US10/917,175 patent/US7666885B2/en not_active Expired - Lifetime
2007
- 2007-04-20 US US11/788,755 patent/US7781463B2/en not_active Expired - Fee Related
- 2007-08-30 CY CY20071101111T patent/CY1106826T1/el unknown

Also Published As

Publication number	Publication date
CN1568310A (zh)	2005-01-19
KR20030025919A (ko)	2003-03-29
ES2288948T3 (es)	2008-02-01
IL152721A0 (en)	2003-06-24
US6872737B2 (en)	2005-03-29
CA2408747A1 (en)	2001-11-15
US7666885B2 (en)	2010-02-23
AU5498101A (en)	2001-11-20
US7781463B2 (en)	2010-08-24
US20050014803A1 (en)	2005-01-20
BR0110734A (pt)	2003-02-04
CA2408747C (en)	2011-04-05
EP1286964B1 (de)	2007-07-04
CY1106826T1 (el)	2012-05-23
CZ296087B6 (cs)	2006-01-11
RU2294931C2 (ru)	2007-03-10
HUP0302002A3 (en)	2007-02-28
DE60129222D1 (de)	2007-08-16
EP1286964A1 (de)	2003-03-05
HUP0302002A2 (hu)	2003-09-29
PL209780B1 (pl)	2011-10-31
CZ20023692A3 (cs)	2003-06-18
MXPA02011079A (es)	2004-08-19
CN100358867C (zh)	2008-01-02
DK1286964T3 (da)	2007-10-01
DE60129222T2 (de)	2008-03-06
US20080033012A1 (en)	2008-02-07
KR100812407B1 (ko)	2008-03-11
AU783615B2 (en)	2005-11-17
US20030195238A1 (en)	2003-10-16
WO2001085685A1 (en)	2001-11-15
PL359671A1 (en)	2004-09-06

Publication	Publication Date	Title
ATE366238T1 (de)	2007-07-15	Heterocyclischen inhibitoren von glycogen synthase kinase gsk-3
DE60215814D1 (de)	2006-12-14	Vinylphenyl-derivate als glk-aktivatoren
SE0102300D0 (sv)	2001-06-26	Compounds
ATE334973T1 (de)	2006-08-15	Chinazolinverbindungen
TW200716617A (en)	2007-05-01	Pyrazole compounds useful as protein kinase inhibitors
NO20025792D0 (no)	2002-12-02	Kinazolinderivater for behandling av tumorer
MY146279A (en)	2012-07-31	Compounds affecting glucokinase
BR0313176A (pt)	2005-06-14	Composições de pirazol úteis como inibidores de gsk-3
GB0112348D0 (en)	2001-07-11	Compounds
ATE358668T1 (de)	2007-04-15	Drogen zur behandlung maligner tumoren
TR200302242T2 (tr)	2004-12-21	Protein kinaz önleyicileri olarak pirolopirimidinler
ATE341545T1 (de)	2006-10-15	Quinolin-derivate und ihre verwendung als inhibitoren der tyrosine kinase
MA28010A1 (fr)	2006-07-03	Derives de piperazine et leur utilisation comme agents therapeutiques
WO2002022602A3 (en)	2002-06-27	Triazole compounds useful as protein kinase inhibitors
DE602004011199D1 (de)	2008-02-21	5-phenylthiazolderivate und deren verwendung als p13-kinase-inhibitoren
DE60108626D1 (de)	2005-03-03	Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b] pyridinen als cyclin-abhängige kinase-hemmer
CA2534634A1 (en)	2005-04-14	Azolidinecarbonitriles and their use as dpp-iv inhibitors
ATE260655T1 (de)	2004-03-15	Verwendung von stickstoffhaltigen aromatischen heterozyklusderivaten zur topischen behandlung von epithelerkrankungen
ATE440835T1 (de)	2009-09-15	Heterozyklische harnstoff-derivate für die behandlung von schmerzen.
MXPA05008331A (es)	2005-09-30	Derivados de 3-(benzoilureido)-tiofeno sustituido, metodo para su produccion y uso de los mismos.
NO20053876D0 (no)	2005-08-18	Karbonylaminosubstituerte acylfenylurederivater, fremgangsmate for deres fremstilling samt anvendelse derav
TH62250A (th)	2004-06-03	ตัวยับยั้ง n-[5-[[[5-แอลคิล-2-ออกซาโซลิล]เมธิล]ไธออล]-2-ไธแอโซลิล]- คาร์บอกแซมีด ของไซคลินดีเพนเดนท์ไคเนส